Cochlear (ASX:COH) receive FDA approval for the Baha sound processor

Company News

by Rachael Jones

Hearing solutions company Cochlear (ASX:COH) has received US Food and Drug Administration (FDA) clearance and CE Mark accreditation for the new Cochlear Baha 6 Max Sound Processor.

This is designed to improve hearing outcomes for people with single-sided deafness, conductive or mixed hearing loss.

The Baha 6 Max is the first of its kind a bone conduction sound processor offering direct streaming from Apple and Android devices.

Direct streaming from Apple devices has been available in the Baha 5 Sound Processor since 2015.

It will be launched across the US and Europe over the coming months.

Shares in Cochlear (ASX:COH) are trading 0.1 per cent higher at $217.49.